Peptides for Healing and Injury Recovery (2026): BPC-157, TB-500, GHK-Cu, KPV and What the Evidence Really Shows

Research Guide · 20 min read · Updated October 2026

The ranking at a glance

How tissue healing works, and where peptides could act

Every tissue heals through roughly the same three overlapping phases, and each peptide is claimed to help with one or more of them:

1. Inflammation (days 0–7). Immune cells clear damaged tissue and release growth signals. Too little inflammation slows healing; too much, or too long, causes damage. KPV and, in animal studies, BPC-157 are said to act here.
2. Proliferation (days 4–21). New blood vessels grow (angiogenesis), fibroblasts migrate in and lay down new collagen. This is where most of the BPC-157, TB-500 and GHK-Cu animal data sit.
3. Remodelling (weeks to months). The new collagen is reorganized and strengthened along lines of load. In tendons this phase can take a year or more, and it’s the phase where loading and rehabilitation matter most.

The key limitation for tendons and ligaments is blood supply. They have far less of it than muscle or skin, which is why they heal slowly. Compounds that promote angiogenesis in animal models are interesting precisely because they target that bottleneck.

BPC-157

BPC-157 (“body protection compound”) is a 15-amino-acid peptide derived from a protein found in human gastric juice. Almost all of its research comes from one group at the University of Zagreb, which has published well over a hundred studies since the early 1990s.

What the animal and cell studies show

• Tendon: in rats with cut Achilles tendons, BPC-157 improved functional, biomechanical and microscopic measures of healing. In cell culture, it increased tendon fibroblast outgrowth, survival and migration (Chang 2011) and growth hormone receptor expression (Chang 2014).
• Blood vessels: it activated the VEGFR2 pathway and promoted angiogenesis (Hsieh 2017), the mechanism most often proposed for its effects.
• Gut: it protected the stomach and intestinal lining across many injury models, its original area of study.
• Muscle, ligament and bone: positive results in rat injury models, reviewed by Gwyer and colleagues in 2019.

What human data exists

Very little. The most cited human report is a 2021 retrospective review of patients with knee pain given BPC-157 injections at a single clinic, with no control group. A small phase 1 trial was registered in the mid-2010s, but no results were ever published. A 2025 systematic review of BPC-157 in orthopaedic sports medicine concluded that human evidence was insufficient to support clinical use.

More: What is BPC-157?, How long does BPC-157 take to work? and Does BPC-157 cause cancer?

TB-500 and thymosin beta-4

This is the most commonly misunderstood compound in the category, because two different things share a reputation.

• Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein found in almost every cell. Its main job is binding actin, the protein that lets cells change shape and move. It is released at wound sites and promotes cell migration, blood vessel formation and reduced inflammation in animal models. It also has real human trials: RegeneRx tested it as eye drops for dry eye and neurotrophic keratitis, and as a gel for skin wounds. The results were mixed: some endpoints improved, primary endpoints often weren’t met, and it hasn’t been approved.
• TB-500 is a short synthetic peptide based on the actin-binding region of Tβ4. It was originally developed for veterinary use in racehorses. Almost all the evidence quoted for TB-500 is actually evidence for full-length Tβ4.

Key Tβ4 findings include faster wound closure in rats (Malinda 1999) and heart repair after experimental heart attacks in mice (Bock-Marquette 2004; Smart 2007). Whether the TB-500 fragment reproduces these effects has barely been studied. See TB-500 in Canada and TB-500 side effects.

GHK-Cu

GHK-Cu is a tiny peptide (glycine-histidine-lysine) bound to a copper ion. It occurs naturally in plasma, saliva and urine, and its levels fall with age. In 1988 researchers showed it stimulated collagen production in fibroblast cultures, and it has since been studied for wound healing, skin remodelling and hair.

Its human evidence is mostly topical and cosmetic: small studies of creams on facial skin reporting improvements in firmness, fine lines and thickness. Gene-expression work suggests GHK modulates a large number of genes involved in tissue repair. That’s an interesting finding, though it doesn’t prove clinical effects. Its blue colour comes from the copper. See GHK-Cu in Canada, Why is GHK-Cu blue? and copper peptides and hair.

KPV

KPV is a three-amino-acid peptide (lysine-proline-valine) taken from the tail end of alpha-melanocyte-stimulating hormone (α-MSH), a natural anti-inflammatory signal. Its main research context is gut inflammation: in a 2008 Gastroenterology study, KPV taken up through the intestinal transporter PepT1 reduced inflammation in mouse colitis models. Later work tested it in colon-targeted nanoparticles.

KPV’s relevance to “healing” is therefore indirect: it is an anti-inflammatory research tool, mainly for the gut and skin. There are no published human trials. Full guide: KPV peptide.

Collagen peptides: the boring one with the best human data

Collagen peptides (hydrolyzed collagen, taken orally) are rarely mentioned alongside BPC-157, but they are the only compound on this page with a meaningful number of randomized, placebo-controlled human trials related to tissue repair:

• Skin: double-blind trials have reported improvements in skin elasticity and wrinkle depth over 8–12 weeks (for example, Proksch 2014).
• Tendon: a small randomized pilot found that specific collagen peptides added to calf-strengthening exercises improved function and pain in Achilles tendinopathy more than exercise alone (Praet 2019).
• Joints: several trials report modest reductions in activity-related joint pain.

The effects are modest and many trials are industry-funded, so they deserve scepticism too. But the contrast is instructive: modest, replicated human effects on one side; dramatic, mostly unreplicated rat effects on the other. Both are worth knowing about.

Blends: BPC/TB, GLOW and KLOW

Research suppliers increasingly sell pre-mixed blends: BPC-157 with TB-500, or larger combinations like “GLOW” (GHK-Cu, BPC-157, TB-500) and “KLOW” (the same plus KPV). The rationale is that the compounds act on different phases of healing: BPC-157 on angiogenesis and the gut, TB-500 on cell migration, GHK-Cu on collagen remodelling, KPV on inflammation.

No study has tested these blends as combinations, in animals or humans. For research, a blend is a practical convenience, but it makes it impossible to attribute an effect to a single compound. That’s why separate vials are usually the better choice for experiments designed to answer a question. We compare them in Wolverine vs GLOW vs KLOW and BPC-157 and TB-500 together.

By tissue: tendon, ligament, muscle, gut, skin

Condition-specific guides: tendonitis, knee pain, shoulder pain and IBS and leaky gut.

Other peptides sometimes called “healing peptides”

The larazotide story is worth remembering. A gut-healing peptide with a clear mechanism and encouraging early data still failed when tested properly in a large trial. That happens often in drug development, and it’s why animal data alone can’t settle the question for BPC-157 or TB-500.

How to read a healing-peptide study

Most healing-peptide claims online trace back to a specific paper. Before you trust the claim, check five things about that paper:

1. Species. Rat, mouse, cell culture or human? Most BPC-157 and TB-500 papers are rat or cell studies.
2. Injury model. A surgically cut tendon in a young rat differs from a degenerative tendinopathy in a 45-year-old runner.
3. Control group. Was there a placebo or untreated group, and was the assessment blinded?
4. Outcome. Microscopic tissue appearance, breaking strength, or what patients care about: pain and function months later?
5. Independence. Has a different laboratory reproduced the result? For BPC-157 in particular, independent replication is the biggest missing piece.

A result that passes all five is strong evidence. Very few results in this field do, which is the honest summary of where healing peptides stand in 2026.

The July 2026 FDA votes, explained

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted on whether several peptides should be added to the list of bulk substances US pharmacists may use in compounding (the 503A “bulks list”).

Three caveats are essential. First, the votes are advisory: FDA’s review staff had recommended against including BPC-157, TB-500, KPV and MOTS-c, and the agency will decide through notice-and-comment rulemaking. Second, being on the bulks list would allow compounding with a prescription. It is not drug approval and says nothing definitive about efficacy. Third, it’s a US process with no direct effect in Canada.

Canada: what Health Canada says

None of these peptides is an authorized drug in Canada. Health Canada’s April 9, 2026 public advisory, “Think twice before injecting peptides bought online,” warned that unauthorized peptides may contain the wrong ingredient, the wrong amount or contaminants, and that it works with CBSA to stop unauthorized shipments. In August 2025 it also named BPC-157, TB-500, GHK-Cu and dozens of other peptides among unauthorized injectable products seized from a Canadian seller marketing them for human use.

Research suppliers like TrueLabs sell these compounds strictly as laboratory reagents, without health claims or human dosing. For how this works legally, see Research peptides in Canada.

Athletes: WADA status

Competitive athletes should know that several healing peptides are explicitly prohibited:

• BPC-157 is listed by WADA as a non-approved substance (section S0), prohibited at all times.
• TB-500 and thymosin beta-4 are prohibited under growth factors and related substances (section S2).
• Growth hormone secretagogues such as CJC-1295 and ipamorelin are prohibited under S2.

Anti-doping tests for these compounds exist and athletes have been sanctioned. Check the current WADA Prohibited List; the rules are updated every January.

Safety questions that remain open

• Cancer: anything that promotes new blood vessel growth raises a theoretical concern about supporting existing tumours. There is no evidence that BPC-157 or TB-500 cause cancer, but there are also no long-term human data to rule out effects on existing cancers. We go through this carefully in Does BPC-157 cause cancer?
• Product quality: independent testing of grey-market products has repeatedly found under-filled vials, wrong compounds and contamination, which is Health Canada’s central concern.
• Unknown long-term effects: there are no long-term human safety studies for BPC-157, TB-500 or KPV.
• Masking injury: anything that reduces pain without restoring tissue strength could encourage return to load too early.

How long tissues normally take to heal

Any claim that a compound “speeds healing” needs a baseline. These are typical timelines for uncomplicated injuries in healthy adults. Individual recovery varies widely with age, severity, loading and general health.

Two things follow. First, because tendons heal slowly, they are where an effective compound would matter most, and also where natural improvement over months can easily be mistaken for a treatment effect. Second, any human study needs to run long enough to cover the remodelling phase. Short studies of pain alone can mislead.

What is proven to speed healing

It’s worth saying plainly, because it’s easy to lose in peptide discussions: the interventions with strong human evidence for soft-tissue recovery are unglamorous.

• Progressive loading. For tendinopathy, structured exercise that gradually increases load is the best-supported treatment.
• Relative rest, not total rest. Immobilization weakens tissue; guided activity strengthens it.
• Adequate protein and energy. Healing tissue needs raw material, and under-eating slows recovery.
• Sleep. Growth hormone release and tissue repair are concentrated in deep sleep.
• Not smoking. Smoking measurably impairs tendon, bone and wound healing.
• Physiotherapy. A good physiotherapist is the highest-value intervention for most sports injuries.

For researchers: designing a comparison

If you’re studying these compounds in vitro, a few design choices make results more meaningful:

1. Use single compounds before blends. Establish each compound’s effect alone, then test combinations to see whether they are additive.
2. Pick the right assay for the claim. Scratch (wound-closure) assays for migration; tube-formation assays for angiogenesis; collagen synthesis assays for remodelling; cytokine panels for inflammation.
3. Include a positive control, such as a known growth factor, so you can judge effect size.
4. Verify identity and purity for every batch. A failed result means nothing if the vial held the wrong compound. See How to read a peptide COA.
5. Handle and store carefully. Peptide degradation is a common, invisible source of null results. See How to store peptides.

Browse TrueLabs research compounds →

FAQ

Related reading

• BPC-157 vs TB-500
• BPC-157 and TB-500 together
• What is BPC-157?
• Tendonitis treatment in Canada
• Peptides for weight loss

References

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PubMed
2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333. PubMed
3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PubMed
4. Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24:1972–1989. PubMed
5. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21:485–495. PubMed
6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PubMed
7. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. PubMed
8. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466–472. PubMed
9. Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34:491–496. PubMed
10. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343–346. PubMed
11. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PubMed
12. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166–178. PubMed
13. Proksch E, et al. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol. 2014;27:113–119. PubMed
14. Praet SFE, et al. Oral supplementation of specific collagen peptides combined with calf-strengthening exercises enhances function and reduces pain in Achilles tendinopathy patients. Nutrients. 2019;11. PubMed
15. The FDA Law Blog. PCAC approves four bulk drug substances for the 503A list. July 2026. FDA Law Blog
16. RAPS. FDA advisory committee backs two more peptides, rejects one for compounding list. July 2026. RAPS
17. Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
18. World Anti-Doping Agency. The Prohibited List. WADA

This article summarizes published research for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.